A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2021-11-10
DOI
10.1093/ijnp/pyab071
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire
- (2020) Clifton Blackwood et al. Patient Preference and Adherence
- The Impact of Mental Illness Stigma on Psychiatric Emergencies
- (2020) Antônio Geraldo da Silva et al. Frontiers in Psychiatry
- Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders
- (2018) Robin Emsley et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia
- (2018) Miquel Bioque et al. EXPERT OPINION ON PHARMACOTHERAPY
- Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications
- (2017) Leslie Citrome Expert Review of Neurotherapeutics
- Clinical improvement, relapse and treatment adherence with paliperidone palmitate 1-month formulation: 1-year treatment in a naturalistic outpatient setting
- (2017) Rosaria Di Lorenzo et al. NORDIC JOURNAL OF PSYCHIATRY
- Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications
- (2017) Leslie Citrome Expert Review of Neurotherapeutics
- Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder
- (2017) Mallik Greene et al. JOURNAL OF MEDICAL ECONOMICS
- Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study
- (2016) Adam J. Savitz et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
- (2016) Christoph U. Correll et al. JOURNAL OF CLINICAL PSYCHIATRY
- A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia
- (2016) Larry Alphs et al. SCHIZOPHRENIA RESEARCH
- Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia
- (2015) Georgia L. Stevens et al. Early Intervention in Psychiatry
- Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia
- (2015) Andreas Schreiner et al. SCHIZOPHRENIA RESEARCH
- Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia
- (2015) Joris Berwaerts et al. JAMA Psychiatry
- Paliperidone palmitate long-acting injection - prospective year-long follow-up of use in clinical practice
- (2013) A. Attard et al. ACTA PSYCHIATRICA SCANDINAVICA
- Prospective Trial of Customized Adherence Enhancement Plus Long-Acting Injectable Antipsychotic Medication in Homeless or Recently Homeless Individuals With Schizophrenia or Schizoaffective Disorder
- (2013) Martha Sajatovic et al. JOURNAL OF CLINICAL PSYCHIATRY
- Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review
- (2012) Mark Taylor et al. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
- Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study
- (2010) Srihari Gopal et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia
- (2010) S Gopal et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study
- (2009) Michelle Kramer et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study
- (2009) David Hough et al. SCHIZOPHRENIA RESEARCH
- Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia
- (2008) Gunnar Morken et al. BMC Psychiatry
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started